ACE-031

Intro

ACE-031 (also called Ramatercept or ACVR2B-Fc) is a recombinant fusion protein of the extracellular domain of human ActRIIB linked to the Fc portion of human IgG1.

It functions as a soluble decoy receptor circulating through the body and competing with cell-surface ActRIIB for ligand binding — sequestering myostatin (GDF-8), GDF-11, activin A, and activin B before they can activate the downstream SMAD2/3 signaling cascade that suppresses muscle protein synthesis. The result is broad removal of the endogenous brake on hypertrophy across all muscle tissue simultaneously.

Developed by Acceleron Pharma, ACE-031 completed a Phase 1 SAD study in 48 postmenopausal healthy women (2009–2012), showing statistically significant lean mass increases at the higher dose cohorts and a half-life of 10–15 days. Phase 2 RCT in ambulatory DMD boys followed (with Shire), using 0.5 mg/kg every 4 weeks and 1 mg/kg every 2 weeks regimens. The trial was halted May 2, 2013 after telangiectasias and epistaxis emerged in the pediatric population. Investigators did not classify these events as serious or severe, but Acceleron and Shire decided the risk:benefit ratio was unacceptable for children already compromised by DMD and corticosteroid co-administration. Phase 1 results were published by Sherman et al. in Muscle & Nerve 2013; Phase 2 results by Campbell et al. in Muscle & Nerve 55:458-464 (2017; 90 Scopus citations).

ACE-031 is mechanistically distinct from selective myostatin antibodies (trevogrumab/REGN1033) and activin A antibodies (garetosmab) — those next-generation compounds were designed to achieve selectivity that ACE-031 lacks. ACE-031 blocks the entire ActRIIB ligand family, explaining both its superior raw efficacy in lean mass accumulation compared to specific antibodies and the vascular AEs driven by activin A blockade. Paradoxically, the 2013 efficacy publication drove gray-market demand: community members read 'it works in humans from a single dose' and concluded the compound was worth pursuing despite clinical discontinuation.

Observed Effects

Phase 1 (Sherman 2013, postmenopausal women, single SC dose): statistically significant lean mass increases at higher dose cohorts across the 0.02–3 mg/kg range.

PK: linear AUC and Cmax; T½ 10–15 days. Phase 2 (Campbell 2017, DMD boys): lean body mass trended upward in the ACE-031 group vs placebo — not statistically significant due to early termination. HighPeptides cites +1.7% lean mass at day 29 from a single 250 mg dose in the Phase 2 protocol. DEXA scan was the measurement method (corpus certainty 0.8). Dose-response confirmed: higher dose produced greater muscle volume effect (corpus certainty 0.8).

Secondary body composition outcomes in Phase 2: bone mineral density trended upward (corpus certainty 0.8); fat mass trended downward (corpus certainty 0.8). These multi-tissue effects reflect the broad ActRIIB ligand blockade — activins regulate bone turnover and fat metabolism as well as muscle. The 6-minute walk test (6MWT), a functional DMD outcome measure, trended toward maintenance in the ACE-031 group vs decline in placebo — not statistically significant. Community interprets the 6MWT trend as further evidence of real-world efficacy in a challenging progressive disease.

FSH suppression is a confirmed pharmacodynamic effect (corpus certainty 0.9). FSH decline persisted past day 57 without returning to baseline. This effect was observed at 1 mg/kg and at 3 mg/kg. It is a mechanistically predictable consequence of blocking activin A and activin B — both are major regulators of pituitary FSH secretion via the ActRIIB receptor expressed at the pituitary level.

Animal data (NHP marmosets, rodent myostatin knockout models): extreme lean mass increases at supraphysiologic doses drove initial development interest. Rodent knockout data often cited in community (body mass near-doubling) do not translate proportionally — satellite cell availability, not myostatin signaling, is the ultimate rate-limiting factor for muscle growth in adults. Community educators explicitly correct this misconception (corpus assertion, certainty 0.75): 'Rate limiting factor for muscle growth is not myostatin alone.'

Field Reports

First-person experience logs with quantified dose/response are essentially non-existent across all community platforms.

The compound has been discussed in depth for 15+ years but almost never actually used at clinical-equivalent doses. Long-running bodybuilding-board discussion acknowledged that few people had actually run the compound even years after the trial halt. Community knowledge derives almost entirely from the published Sherman 2013 and Campbell 2017 papers, marketing summaries, and mechanistic inference — not cycle logs.

The cost barrier is the primary reason: at gray-market pricing, a single clinical-equivalent dose for a 100 kg user runs $500–3,000+. A 12-week protocol at 1 mg/kg q2w costs $3,500–7,000. Even users who wanted to experiment could not afford consistent dosing. The secondary barrier is availability — gray-market supply has always been intermittent, with intermittent small-lot availability.

Marketing circulated a '60% muscle gain' claim that experienced community members recognize as fabricated. The actual Phase 1 data (significant lean mass increase from a single dose in a controlled trial) is compelling without inflation. The community's risk assessment for healthy adults versus the pediatric DMD population is plausible: no corticosteroid co-administration, better vascular baseline, lower baseline disease burden. But this reasoning is speculation — the only safety data in healthy adults (Phase 1, postmenopausal women) was not designed to assess vascular endpoints at the doses where Phase 2 AEs emerged.

Newer practitioner and GLP-1-community discussion has reframed ACE-031 as a possible lean-mass preservation agent during aggressive caloric deficit rather than only a standalone mass builder.

Community Consensus

Early community analysis before human data leaned heavily on preclinical publications, elite-muscle-genetics analogies, and the "myostatin lottery" framing.

Community reaction was immediate and superlative, but cost concerns appeared just as early and have not meaningfully changed in 15 years.

The May 2, 2013 halt had the opposite of its intended dampening effect. Community discussion documented the halt date and produced the canonical interpretation: DMD boys on corticosteroids were a vulnerable population; the AEs were mild (not serious, not severe by classification); the halt was population-specific, not compound-inherently-dangerous. When Acceleron published the Phase 1 human proof-of-concept data (Sherman 2013) showing lean mass increases from a single dose in healthy women, community concluded 'the stuff works' — and gray-market supply emerged directly from the efficacy publication. Community discussion treated the Phase 1 efficacy publication as the moment gray-market interest became inevitable.

Community acknowledges the steroid-user ceiling effect as a genuine limitation: high-dose androgens substantially suppress endogenous myostatin expression, making external ActRIIB blockade potentially redundant for existing steroid users (certainty 0.5 — explicitly uncertain in corpus). GLP-1 use cases represent the most credible new use-case framing (2024–2025): myostatin blockade during aggressive GLP-1-driven fat loss to offset lean mass loss. Post-2013 bodybuilding discussion showed appropriate skepticism about marketing claims while maintaining interest in the compound's genuine mechanism. Supply intermittency compounds the cost barrier. WADA S4.3 prohibition limits the compound to non-tested athletes and non-competitive researchers.

Risks & Monitoring

Phase 2 halt triggers: telangiectasias (spider veins) and epistaxis (nosebleeds) in DMD boys on concurrent corticosteroids.

Investigators classified these as neither serious nor severe. The halt was a precautionary strategic decision by Acceleron/Shire — unacceptable risk layering in a pediatric population with DMD-related vascular compromise potentiated by corticosteroid-fragmented vascular tone. Community interpretation: the AEs were population-specific (steroid-potentiated, pediatric disease context), not evidence of inherent compound danger in healthy adults. This interpretation is plausible but untested — no vascular endpoint data from healthy adults exists.

Injection-site adverse events confirmed from corpus (certainty 0.8 each): swelling, erythema, post-injection pain, and headache. These were present in Phase 1 and Phase 2. Community protocol guidance — site rotation, slow SC push, refrigerated storage — addresses this cluster.

FSH suppression is a confirmed endocrine AE (certainty 0.9). Persistent past day 57. In women of reproductive age: cycle disruption and fertility impairment expected for weeks to months post-dose. In men: spermatogenesis reduction possible via gonadal FSH dependence. Standard PCT agents (SERMs, HCG) are not designed for ActRIIB-pathway FSH suppression — their role here is uncertain.

Three critical uninvestigated safety gaps (corpus, certainty 0.9 each): blood pressure was NOT measured in any trial — explicitly flagged as an 'unfortunate omission' by corpus educators; BP elevation is an uninvestigated inference (certainty 0.6) given activin's vascular biology role. Inflammatory markers were NOT measured. Organ weight and organ size were NOT measured despite full-body MRI being available (used for muscle, not organs). These are genuine unknowns, not cleared risks. Whether systemic ActRIIB blockade produces cardiac, hepatic, or pulmonary effects is unknown (corpus, certainty 0.5 for organ effects).

Gray-market specific risks: no consumer-accessible identity verification for a ~100 kDa Fc-fusion protein. Mass spectrometry required for confirmation. Visual inspection catches only severe denaturation. Product could be mislabeled, underdosed, or denatured without detection.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Maximal lean mass accumulation: 1–3 mg/kg SC every 2 weeks for 12 weeks, following Phase 2 Regimen 2 scaled to Phase 1 upper doses.

FSH and LH at baseline and post-cycle. Blood pressure weekly. CBC and CMP at baseline. FSH check at 4 and 8 weeks post-last dose. Note the dose-response relationship (higher dose → greater muscle volume effect, corpus certainty 0.8) supports upper-range dosing if cost allows.

Body recomposition or lean mass preservation during GLP-1 cycles: 0.5–1 mg/kg SC every 4 weeks for 8–12 weeks. Rationale: exploit the long T½ to maintain partial ActRIIB blockade at reduced cost and injection frequency. Mechanistically paired with GLP-1 agonist for simultaneous fat-loss drive (GLP-1) and lean mass preservation (ACE-031 myostatin blockade). No clinical trial data for this combination — rationale is mechanistically sound but unvalidated.

Budget protocol (acknowledged inadequate): 0.1–0.5 mg/kg SC every 4 weeks for 12 weeks. No human efficacy data at this dose range. Realistic expectation: subclinical or undetectable lean mass effect. Primary remaining risk even at very low doses: FSH suppression threshold unknown, gray-market product cost spent without confidence in efficacy.

Steroid-user caution: if the user is already running high-dose anabolic steroids, ACE-031 benefit may be marginal or negligible. High-dose androgens substantially suppress endogenous myostatin expression — if myostatin is already near-suppressed, external ActRIIB blockade removes a brake that is already partially released. Corpus educator certainty for myostatin inhibitor benefit in existing steroid users: 0.5 (explicitly uncertain).

Dosing Details

Phase 1 (Sherman 2013): single SC dose, range 0.02–3 mg/kg in postmenopausal women. PK: linear AUC and Cmax across the dose range; T½ 10–15 days.

Phase 2 (Campbell 2017): Regimen 1 = 0.5 mg/kg SC every 4 weeks × 4 doses over 12 weeks; Regimen 2 = 1 mg/kg SC every 2 weeks × 7 doses over 12 weeks. Trial halted after Regimen 2. These are the only human dosing data available.

Community extrapolation: the Phase 2 Regimen 2 (1 mg/kg q2w) is adopted as the baseline template, scaled upward to 1–3 mg/kg SC every 2 weeks for 12 weeks. Corpus documents 2 mg/kg q2w × 3 months as a community-endorsed upper-range protocol (certainty 0.7). Some use every-4-week intervals, exploiting the 10–15 day T½ to halve cost while maintaining some receptor blockade between injections.

Low-dose workaround: users who cannot afford clinical-equivalent dosing attempt 0.1–0.5 mg/kg per injection. No human efficacy data exists for body composition at these doses. Whether partial ActRIIB blockade at low doses produces measurable lean mass effect is unknown. The community rationale is 'any blockade may contribute marginal benefit.'

Cost reality at current gray-market pricing: 1 mg/kg q2w for 12 weeks (7 doses) for a 100 kg user = 700 vials × $5–10/vial = $3,500–7,000. At 3 mg/kg, triple these figures.

Stacks & Alternatives

Emerging community use-case. GLP-1 agonists produce fat loss but can cause lean mass loss at aggressive caloric deficits. ACE-031's ActRIIB blockade theoretically offsets lean mass loss while GLP-1 drives fat reduction — simultaneous fat-loss driver plus lean mass preservation driver. No clinical trial data for this combination. Mechanistically sound but unvalidated in humans.

Community combines systemic (ACE-031) and local (ACE-083 IM at target muscle) myostatin pathway blockade for total-body recomposition plus site-specific enhancement. ACE-031 handles global lean mass increase; ACE-083 targets a lagging muscle group specifically. Used by advanced bodybuilders seeking to exploit both systemic and localized mechanisms. No safety data for combination; FSH suppression compounds.

Combining two distinct anabolic mechanisms: androgen receptor activation (testosterone) and ActRIIB pathway blockade (ACE-031). However, the critical caveat applies: if high-dose androgens have already substantially suppressed endogenous myostatin, adding ACE-031 may produce minimal additive benefit (corpus educator certainty 0.5 — genuinely uncertain). FSH suppression from both agents compounds. BP monitoring essential.

Alternatives

Stack Cost

Practical Setup

Storage and handling: ACE-031 is a large Fc-fusion protein with cold-chain, agitation, and denaturation risk.

Cloudiness, particulates, or gelation are quality red flags. Handling details are not standardized and should not be treated as reader-specific compounding or injection guidance.

Quality verification: accessible verification is limited for a roughly 100 kDa fusion protein. Visual inspection catches only severe denaturation; mislabeled, underdosed, or denatured product remains a fundamental risk for large protein biologics outside regulated clinical supply.

WADA prohibition: S4.3 (Metabolic Modulators - myostatin inhibitors and activin receptor blockers). Detection window is likely long given the 10-15 day half-life and persistence as an Fc-fusion protein in serum. Any athlete subject to anti-doping rules cannot use ACE-031.

Compound status: ACE-031 has no active IND, no active development program, and no commercial path. Any non-trial use occurs without regulatory oversight, quality control, or clinical monitoring support. FSH monitoring and blood pressure monitoring are the minimum safety precautions warranted given the confirmed endocrine effect and the uninvestigated vascular signal.

Mechanism Deep Dive

ACE-031 is a broad ActRIIB ligand trap. The extracellular domain of ActRIIB — the portion that normally faces the extracellular space and binds incoming myostatin-family ligands — is fused to the Fc portion of IgG1.

The Fc component extends the half-life to 10–15 days via FcRn recycling (same mechanism responsible for IgG's long half-life). The resulting circulating protein binds myostatin (GDF-8), GDF-11, activin A, and activin B with high affinity, sequestering them in the extracellular space before they can reach cell-surface ActRIIB.

When myostatin and activins bind membrane-bound ActRIIB, the downstream signal cascades through SMAD2 and SMAD3 phosphorylation, which suppress mTOR pathway activity, upregulate atrogin-1 and MuRF1 (ubiquitin ligases driving protein catabolism), and inhibit satellite cell activation. ACE-031 blockade reduces SMAD2/3 phosphorylation — releasing the brake on protein synthesis, reducing catabolism, and enabling greater satellite cell responsiveness. Net effect: enhanced hypertrophy signal in all skeletal muscle simultaneously.

The rate-limiting factor caveat: corpus educators explicitly correct the naive community framing. Myostatin is not the sole rate-limiting factor for muscle growth. Satellite cell availability — the number of new nuclei that can be added to muscle fibers to support hypertrophy — is the functional ceiling that ACE-031 cannot overcome. This is why rodent myostatin knockout models (lifelong absence of signaling brake from birth) show near-doubling of body mass while adult pharmacologic blockade in humans produces impressive but not proportionally extreme lean mass gains.

FSH suppression mechanism: activin A and activin B are major regulators of pituitary FSH secretion via the ActRIIB receptor expressed at the pituitary level. By blocking both activins systemically, ACE-031 removes the pituitary activin signal — FSH falls. This is mechanism-predictable and confirmed at 1 mg/kg and 3 mg/kg in the Phase 1 data.

Vascular AE mechanism: activin A regulates vascular biology — endothelial function, vascular remodeling, angiogenesis. Telangiectasias (disordered angiogenesis producing spider veins) and epistaxis (fragile mucosal vessels) are consistent with disrupted vascular activin A signaling. This liability is why next-generation myostatin-pathway compounds (trevogrumab = myostatin-only antibody; garetosmab = activin A-only antibody) were specifically designed to avoid ACE-031's broad ligand trap mechanism.

Evidence Index